BHMT and steatosis: Teng et al. reported that BHMT1 heterozygotes exhibited the decrease of BHMT1 activity, but no change of plasma Hcy, and hepatic TG concentration, and BHMT-/- mice displayed increased hepatic/serum Hcy levels, and severe liver injury and lipid deposition without HFD challenge.22 Although BHMT1 expression was decreased in obese mouse livers, hepatic RIMKLA overexpression phosphorylated its T45 site to ameliorate HHcy and steatosis without affecting the protein level, suggesting that modulation of BHMT1 activity was sufficient to attenuate HHcy and hepatic lipid deposition.